LncRNA HCP5-Encoded Protein Regulates Ferroptosis to Promote the Progression of Triple-Negative Breast Cancer.

Xiao Tong, Zhengling Yu, Jiani Xing, Haizhou Liu, Shunheng Zhou, Yu'e Huang, Jing Lin, Wei Jiang, Lihong Wang
Author Information
  1. Xiao Tong: Department of Pathophysiology, Medical College, Southeast University, Nanjing 210009, China.
  2. Zhengling Yu: Department of Pathophysiology, Medical College, Southeast University, Nanjing 210009, China.
  3. Jiani Xing: Department of Pathophysiology, Medical College, Southeast University, Nanjing 210009, China.
  4. Haizhou Liu: Department of Biomedical Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing 211106, China.
  5. Shunheng Zhou: Department of Biomedical Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing 211106, China. ORCID
  6. Yu'e Huang: Department of Biomedical Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing 211106, China.
  7. Jing Lin: Institute of Cancer Prevention and Treatment, Heilongjiang Academy of Medical Science, Harbin Medical University, Harbin 150081, China.
  8. Wei Jiang: Department of Biomedical Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing 211106, China. ORCID
  9. Lihong Wang: Department of Pathophysiology, Medical College, Southeast University, Nanjing 210009, China.

Abstract

BACKGROUND: Long non-coding RNAs (lncRNAs) are a class of RNA molecules that are longer than 200 nucleotides and were initially believed to lack encoding capability. However, recent research has found open reading frames (ORFs) within lncRNAs, suggesting that they may have coding capacity. Despite this discovery, the mechanisms by which lncRNA-encoded products are involved in cancer are not well understood. The current study aims to investigate whether lncRNA HCP5-encoded products promote triple-negative breast cancer (TNBC) by regulating ferroptosis.
METHODS: We used bioinformatics to predict the coding capacity of lncRNA HCP5 and conducted molecular biology experiments and a xenograft assay in nude mice to investigate the mechanism of its encoded products. We also evaluated the expression of the HCP5-encoded products in a breast cancer tissue microarray.
RESULTS: Our analysis revealed that the ORF in lncRNA HCP5 can encode a protein with 132-amino acid (aa), which we named HCP5-132aa. Further experiments showed that HCP5-132aa promotes TNBC growth by regulating GPX4 expression and lipid ROS level through the ferroptosis pathway. Additionally, we found that the breast cancer patients with high levels of HCP5-132aa have poorer prognosis.
CONCLUSIONS: Our study suggests that overexpression of lncRNA HCP5-encoded protein is a critical oncogenic event in TNBC, as it regulates ferroptosis. These findings could provide new therapeutic targets for the treatment of TNBC.

Keywords

References

  1. Theranostics. 2021 Mar 4;11(10):4929-4944 [PMID: 33754036]
  2. Cells. 2019 May 20;8(5): [PMID: 31137555]
  3. Genome Biol. 2014;15(12):550 [PMID: 25516281]
  4. Cancers (Basel). 2022 May 09;14(9): [PMID: 35565466]
  5. Front Pharmacol. 2018 Nov 13;9:1295 [PMID: 30483132]
  6. J Exp Med. 2020 Mar 2;217(3): [PMID: 31816634]
  7. Cell Death Differ. 2016 Mar;23(3):369-79 [PMID: 26794443]
  8. Cell. 2017 Oct 5;171(2):273-285 [PMID: 28985560]
  9. Oncol Lett. 2013 Aug;6(2):393-400 [PMID: 24137335]
  10. Signal Transduct Target Ther. 2020 Jun 30;5(1):108 [PMID: 32606298]
  11. Cancer Med. 2019 Aug;8(9):4389-4403 [PMID: 31215169]
  12. Nucleic Acids Res. 2016 Jan 4;44(D1):D447-56 [PMID: 26527722]
  13. Mol Cell. 2017 Oct 5;68(1):171-184.e6 [PMID: 28985503]
  14. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [PMID: 19474385]
  15. OMICS. 2012 May;16(5):284-7 [PMID: 22455463]
  16. Mol Ther. 2016 Oct;24(10):1806-1822 [PMID: 27434586]
  17. Cell Death Dis. 2018 Mar 7;9(3):372 [PMID: 29515098]
  18. Int J Cancer. 2021 Apr 5;: [PMID: 33818764]
  19. Proc Natl Acad Sci U S A. 2011 May 24;108(21):8773-8 [PMID: 21555567]
  20. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5 [PMID: 23193258]
  21. Pharmacol Res. 2018 Mar;129:151-155 [PMID: 29133213]
  22. Mol Cancer. 2020 Feb 4;19(1):22 [PMID: 32019587]
  23. Nucleic Acids Res. 2011 Jan;39(Database issue):D38-51 [PMID: 21097890]
  24. Nature. 1992 Apr 9;356(6369):523-6 [PMID: 1560825]
  25. Nature. 2019 Aug;572(7769):402-406 [PMID: 31341276]
  26. Nature. 2019 Nov;575(7784):688-692 [PMID: 31634900]
  27. Genome Biol. 2013 Apr 25;14(4):R36 [PMID: 23618408]
  28. Cancer Lett. 2015 Jan 28;356(2 Pt B):971-7 [PMID: 25444922]
  29. Eur Rev Med Pharmacol Sci. 2018 Aug;22(15):4812-4819 [PMID: 30070314]
  30. Front Oncol. 2021 Jan 14;10:622294 [PMID: 33520729]
  31. Methods Mol Biol. 2017;1550:339-368 [PMID: 28188540]
  32. Curr Opin Genet Dev. 2018 Feb;48:8-15 [PMID: 29054012]
  33. Nucleic Acids Res. 2019 Jan 8;47(D1):D221-D229 [PMID: 30395267]
  34. Genetics. 2013 Mar;193(3):651-69 [PMID: 23463798]
  35. Cell. 2012 May 25;149(5):1060-72 [PMID: 22632970]

Word Cloud

Created with Highcharts 10.0.0cancerlncRNAproductsbreastTNBCferroptosisHCP5-encodedHCP5proteinHCP5-132aalncRNAsfoundcodingcapacitystudyinvestigatetriple-negativeregulatingexperimentsencodedexpressionROSBACKGROUND:Longnon-codingRNAsclassRNAmoleculeslonger200nucleotidesinitiallybelievedlackencodingcapabilityHoweverrecentresearchopenreadingframesORFswithinsuggestingmayDespitediscoverymechanismslncRNA-encodedinvolvedwellunderstoodcurrentaimswhetherpromoteMETHODS:usedbioinformaticspredictconductedmolecularbiologyxenograftassaynudemicemechanismalsoevaluatedtissuemicroarrayRESULTS:analysisrevealedORFcanencode132-aminoacidaanamedshowedpromotesgrowthGPX4lipidlevelpathwayAdditionallypatientshighlevelspoorerprognosisCONCLUSIONS:suggestsoverexpressioncriticaloncogeniceventregulatesfindingsprovidenewtherapeutictargetstreatmentLncRNAHCP5-EncodedProteinRegulatesFerroptosisPromoteProgressionTriple-NegativeBreastCancer

Similar Articles

Cited By